At this year’s European Society for Medical Oncology (ESMO) Annual Meeting, pharmaphorum web editor Nicole Raleigh spoke with ...

As pharmaphorum reported during ESMO 2025, fresh from a return to oncology with the FDA approval of zongertinib as a ...

Merck & Co’s $394 million acquisition of Viralytics has stoked interest in oncolytic viruses, a class of drugs that have been in the shadow of the checkpoint inhibitors and CAR-T therapies that are ...

According to Boehringer, Hernexeos achieved a 77% objective response rate (OOR) in a cohort of previously untreated HER2+ NSCLC patients in Beamion Lung-1, with 8% complete responses and 69% partial ...

The Galleri multi-cancer early detection (MCED) test – which looks for around 50 different types – achieved a seven-fold increase in cancer detection when added to standard screening tests for breast, ...

Germany's Merck KGaA is looking at making further acquisitions to boost its business, according to chief executive Belén Garijo. The CEO – who is due to step down next April after five years in the ...

Eli Lilly has built the case for its oral GLP-1 agonist orforglipron with two more phase 3 readouts, including new data showing that it can improve blood glucose compared to a go-to therapy for type 2 ...

AstraZeneca has become the second pharma group, after Pfizer, to reach an agreement with the Trump administration on a deal to reduce the price of its medicines in the US. President Trump said AZ "is ...

Johnson & Johnson has said it wants to spin off its orthopaedics division as part of an effort to redirect its business towards higher-growth areas. The announcement – made as the company raised its ...

MSD's confidence in its anti-TL1A antibody tulisokibart in inflammatory diseases has been made apparent by a decision to start trials of the drug in three more indications. Already in phase 3 testing ...

Roche has dipped its toe in the M&A water with an agreement to buy US biotech 89bio and its late-stage candidate for metabolic dysfunction-associated steatohepatitis (MASH). The $14.50-per-share deal ...

Eli Lilly has selected Houston, Texas, as the location for a major new facility for active pharmaceutical ingredients (APIs) in the US that will support its fast-growing weight-loss business. The ...